Latest Pharma Insights
NIH Hub Developing Organoids For Research Among HHS Steps Away From Animal Testing
HHS announcements of “agency-wide actions” on reducing animal testing includes closing NIH’s last beagle laboratory and more than $88m for NIH biomedical infrastructure projects nationwide.
HBW Insight - September 22, 2026
HHS announcements of “agency-wide actions” on reducing animal testing includes closing NIH’s last beagle laboratory and more than $88m for NIH biomedical infrastructure projects nationwide.
HBW Insight - September 22, 2026
US FDA Expects To Spur Options To Animal Testing By Inserting ‘Nonclinical’ In Regulatory Language
FDA says it’s “optimistic fostering the use of scientifically valid NAMs will lead to a reduced need for animal testing and to the use of fewer animals and of animals lower on the phylogenetic scale,” but “there remain areas where animal testing is important necessary.”
HBW Insight - September 22, 2026
FDA says it’s “optimistic fostering the use of scientifically valid NAMs will lead to a reduced need for animal testing and to the use of fewer animals and of animals lower on the phylogenetic scale,” but “there remain areas where animal testing is important necessary.”
HBW Insight - September 22, 2026
Bioengineered Cosmetics Have Direct Line To UK Regulators Under New OPSS Sandbox; UK Reg Roundup
Cosmetics will be a test case as the UK’s Office for Product Safety and Standards kicks off an initiative to foster innovation while ensuring product safety. Separately, the UK diverges from the European Commission on silver, hexyl salicylate concentration levels.
HBW Insight - September 22, 2026
Cosmetics will be a test case as the UK’s Office for Product Safety and Standards kicks off an initiative to foster innovation while ensuring product safety. Separately, the UK diverges from the European Commission on silver, hexyl salicylate concentration levels.
HBW Insight - September 22, 2026
Withings Adds AI Heart And Lung Analysis To FDA-Cleared BeamO Home Health Device
Withings is launching StethO Sense, a third-party service that analyzes cardiac and respiratory sounds in children and adults starting Oct. 1. The product uses Withings’ FDA-cleared BeamO handheld device as part of a wider effort to bring clinical-grade health checks to families.
Medtech Insight - September 22, 2026
Withings is launching StethO Sense, a third-party service that analyzes cardiac and respiratory sounds in children and adults starting Oct. 1. The product uses Withings’ FDA-cleared BeamO handheld device as part of a wider effort to bring clinical-grade health checks to families.
Medtech Insight - September 22, 2026
Strategic Intent: Rubedo’s ‘Seno-Adaptive’ Bet On Longevity Medicine
In this episode of Strategic Intent, Rubedo Life Sciences CEO Frederick Beddingfield discusses turning aging biology into drugs, Rubedo’s “seno-adaptive” approach, its AI-enabled platform and pipeline strategy.
In Vivo - September 22, 2026
In this episode of Strategic Intent, Rubedo Life Sciences CEO Frederick Beddingfield discusses turning aging biology into drugs, Rubedo’s “seno-adaptive” approach, its AI-enabled platform and pipeline strategy.
In Vivo - September 22, 2026
J&J’s Multibillion-Dollar Caplyta Ambitions Backed By New Data In Bipolar Mania
The company reported results from the first of two Phase III clinical trials in bipolar mania, which could become the antipsychotic’s fifth US indication.
Scrip - September 21, 2026
The company reported results from the first of two Phase III clinical trials in bipolar mania, which could become the antipsychotic’s fifth US indication.
Scrip - September 21, 2026
Beacon Ready To Approach Regulators With Gene Therapy For XLRP
With successful Phase II/III data for laru-zova in X-linked retinitis pigmentosa, Beacon hopes it can bring the first drug therapy to about 20,000 patients in the US, EU and UK with the retinal disease.
Scrip - September 21, 2026
With successful Phase II/III data for laru-zova in X-linked retinitis pigmentosa, Beacon hopes it can bring the first drug therapy to about 20,000 patients in the US, EU and UK with the retinal disease.
Scrip - September 21, 2026
Cue’s CSU Data Lands In The Pocket, Showing Benefit Over Xolair
The company expects to initiate a Phase IIb/III registration trial testing the anti-IgE IgG1 antibody in CSU and a Phase II study in food allergy, based on the results of a Phase II trial in China.
Scrip - September 21, 2026
The company expects to initiate a Phase IIb/III registration trial testing the anti-IgE IgG1 antibody in CSU and a Phase II study in food allergy, based on the results of a Phase II trial in China.
Scrip - September 21, 2026
Telix’s $1.65bn ITM Deal Brings Isotope Supply And Therapeutics Under One Roof
By combining its therapeutic and commercial platform with ITM’s isotope manufacturing business, Telix is seeking to build a more vertically integrated radiopharma operation.
Scrip - September 21, 2026
By combining its therapeutic and commercial platform with ITM’s isotope manufacturing business, Telix is seeking to build a more vertically integrated radiopharma operation.
Scrip - September 21, 2026
Bayer Legacy Drug Clean-Up Continues With Stivarga Sale
Deal Snapshot: The company is linking up with fellow German firm Grünenthal which will acquire its soon-to-be off-patent cancer blockbuster in a deal worth up to €375m.
Scrip - September 21, 2026
Deal Snapshot: The company is linking up with fellow German firm Grünenthal which will acquire its soon-to-be off-patent cancer blockbuster in a deal worth up to €375m.
Scrip - September 21, 2026
Takeda-Dr Reddy’s Secure First-Mover Window For Qdenga In India, Dengvaxia Out
Takeda has partnered with Dr Reddy’s in India for distribution of its dengue vaccine, which currently has a clear runway in a market where dengue cases have risen elevenfold in two decades.
Scrip - September 21, 2026
Takeda has partnered with Dr Reddy’s in India for distribution of its dengue vaccine, which currently has a clear runway in a market where dengue cases have risen elevenfold in two decades.
Scrip - September 21, 2026
Pipeline Watch: Telix And Pharming Secure FDA Approvals
The FDA approved Telix’s glioma PET imaging agent and expanded Pharming’s Joenja to young APDS patients, while Akeso and BioNTech posted promising Phase III survival data.
Scrip - September 21, 2026
The FDA approved Telix’s glioma PET imaging agent and expanded Pharming’s Joenja to young APDS patients, while Akeso and BioNTech posted promising Phase III survival data.
Scrip - September 21, 2026
Novo Looks To Direct-To-Consumer And Diversification To Lift Growth
The company wants to build on the Wegovy pill's success but its new forecast of sector-average growth to 2030 has seen its share price decline again.
Scrip - September 21, 2026
The company wants to build on the Wegovy pill's success but its new forecast of sector-average growth to 2030 has seen its share price decline again.
Scrip - September 21, 2026
The Shift Toward Precision Immunology in Rheumatology Trials
How biomarker-driven strategies are reshaping patient selection, trial design and clinical development in autoimmune disease.
Scrip - September 21, 2026
How biomarker-driven strategies are reshaping patient selection, trial design and clinical development in autoimmune disease.
Scrip - September 21, 2026
Six Chinese Drugs On Course For Blockbuster Status As Five-Year Plan Sets The Bar
China's government is targeting a minimum of five blockbuster drugs by 2030. At least six Chinese-developed molecules are forecast to cross the $1bn mark in that time.
Scrip - September 21, 2026
China's government is targeting a minimum of five blockbuster drugs by 2030. At least six Chinese-developed molecules are forecast to cross the $1bn mark in that time.
Scrip - September 21, 2026
Withings Adds AI Heart And Lung Analysis To FDA-Cleared BeamO Home Health Device
Withings is launching StethO Sense, a third-party service that analyzes cardiac and respiratory sounds in children and adults starting Oct. 1. The product uses Withings’ FDA-cleared BeamO handheld device as part of a wider effort to bring clinical-grade health checks to families.
Medtech Insight - September 22, 2026
Withings is launching StethO Sense, a third-party service that analyzes cardiac and respiratory sounds in children and adults starting Oct. 1. The product uses Withings’ FDA-cleared BeamO handheld device as part of a wider effort to bring clinical-grade health checks to families.
Medtech Insight - September 22, 2026
NIH Hub Developing Organoids For Research Among HHS Steps Away From Animal Testing
HHS announcements of “agency-wide actions” on reducing animal testing includes closing NIH’s last beagle laboratory and more than $88m for NIH biomedical infrastructure projects nationwide.
HBW Insight - September 22, 2026
HHS announcements of “agency-wide actions” on reducing animal testing includes closing NIH’s last beagle laboratory and more than $88m for NIH biomedical infrastructure projects nationwide.
HBW Insight - September 22, 2026
US FDA Expects To Spur Options To Animal Testing By Inserting ‘Nonclinical’ In Regulatory Language
FDA says it’s “optimistic fostering the use of scientifically valid NAMs will lead to a reduced need for animal testing and to the use of fewer animals and of animals lower on the phylogenetic scale,” but “there remain areas where animal testing is important necessary.”
HBW Insight - September 22, 2026
FDA says it’s “optimistic fostering the use of scientifically valid NAMs will lead to a reduced need for animal testing and to the use of fewer animals and of animals lower on the phylogenetic scale,” but “there remain areas where animal testing is important necessary.”
HBW Insight - September 22, 2026
Bioengineered Cosmetics Have Direct Line To UK Regulators Under New OPSS Sandbox; UK Reg Roundup
Cosmetics will be a test case as the UK’s Office for Product Safety and Standards kicks off an initiative to foster innovation while ensuring product safety. Separately, the UK diverges from the European Commission on silver, hexyl salicylate concentration levels.
HBW Insight - September 22, 2026
Cosmetics will be a test case as the UK’s Office for Product Safety and Standards kicks off an initiative to foster innovation while ensuring product safety. Separately, the UK diverges from the European Commission on silver, hexyl salicylate concentration levels.
HBW Insight - September 22, 2026
Sandoz Receives Canadian Semaglutide Approval Amid Dr Reddy’s Supply Shortages
Canada’s regulator has issued marketing authorizations for Sandoz’s semaglutide, a GLP-1 receptor agonist injection and a generic version of Ozempic.
Generics Bulletin - September 21, 2026
Canada’s regulator has issued marketing authorizations for Sandoz’s semaglutide, a GLP-1 receptor agonist injection and a generic version of Ozempic.
Generics Bulletin - September 21, 2026
Regeneron Sees Eylea HD Biosimilars As ‘Very, Very, Very Unlikely’ In 2027
Regeneron sees a 2027 biosimilar challenge to Eylea HD (aflibercept) as highly unlikely, citing development timelines and patent protection, while additional 2mg competitors are expected to intensify pricing pressure.
Generics Bulletin - September 21, 2026
Regeneron sees a 2027 biosimilar challenge to Eylea HD (aflibercept) as highly unlikely, citing development timelines and patent protection, while additional 2mg competitors are expected to intensify pricing pressure.
Generics Bulletin - September 21, 2026
IGBA Seeks To Emphasize Value With Global Biosimilars Week
This year’s Global Biosimilars Week awareness campaign from the IGBA is less than a month away, with the event running from Oct. 19-24 and focusing on realizing the global value of biosimilars.
Generics Bulletin - September 21, 2026
This year’s Global Biosimilars Week awareness campaign from the IGBA is less than a month away, with the event running from Oct. 19-24 and focusing on realizing the global value of biosimilars.
Generics Bulletin - September 21, 2026
Generics Line Up Early For Europe’s 2028 JAKi Patent Cliffs
Gedeon Richter and Zentiva have secured CHMP backing for generic rivals to Xeljanz and Jakavi, adding to a growing queue of challengers positioning ahead of key European patent expiries in 2028.
Generics Bulletin - September 21, 2026
Gedeon Richter and Zentiva have secured CHMP backing for generic rivals to Xeljanz and Jakavi, adding to a growing queue of challengers positioning ahead of key European patent expiries in 2028.
Generics Bulletin - September 21, 2026
Strategic Intent: Rubedo’s ‘Seno-Adaptive’ Bet On Longevity Medicine
In this episode of Strategic Intent, Rubedo Life Sciences CEO Frederick Beddingfield discusses turning aging biology into drugs, Rubedo’s “seno-adaptive” approach, its AI-enabled platform and pipeline strategy.
In Vivo - September 22, 2026
In this episode of Strategic Intent, Rubedo Life Sciences CEO Frederick Beddingfield discusses turning aging biology into drugs, Rubedo’s “seno-adaptive” approach, its AI-enabled platform and pipeline strategy.
In Vivo - September 22, 2026